Akira Nakakami

Dr. Akira Nakakami

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2025 in Breast Cancer
Verified
Journal Article
Open access
PDF file
Manabu FutamuraManabu Futamura
Manabu Futamura
YNYasuko Nagao
Yasuko Nagao
YTYukiko Takai
Yukiko Takai
YNYoshimi Niwa
Yoshimi Niwa
ANAkira Nakakami
Akira Nakakami
NMNobuhisa Matsuhashi
Nobuhisa Matsuhashi
Background: Radiofrequency ablation (RFA) is a minimally invasive technique employed in the management of small breast tumors. RFA involves the delivery of a high-frequency current through a needle electrode under ultrasound guidance. In Japan, RFA has been covered by insurance since 2023 as a localized treatment option for early-stage breast cancers. Methods: We retrospectively analyzed the data of patients who underwent RFA at our institution between February 2016 and March 2025. Breast density was classified into four categories based on the Breast Imaging Reporting and Data System. Associations between breast density and RFA parameters, including ablation temperature, time, and impedance, were evaluated. Results: A total of 50 breasts in 49 female patients were treated with RFA. The mean peak ablation temperature recorded after the cooling break was 81.0 ± 8.0 °C. Increased breast density was significantly associated with high temperatures. The mean ablation time until break was 446 ± 139 s, indicating a trend toward prolonged durations in cases involving denser breast tissue. The mean initial and final impedance values were 208 ± 72.3 Ω and 161 ± 66.5 Ω, respectively. Fat-rich breasts exhibited significantly higher impedance values at both time points. Conclusion: Fatty breast tissue is associated with higher impedance, lower peak temperatures, and shorter ablation times, potentially resulting in insufficient ablation. Breast density should be considered when planning RFA to ensure optimal treatment efficacy.

21 June 2025 in Cells
Verified
Journal Article
Open access
PDF file
YTYoshihisa Tokumaru
Yoshihisa Tokumaru
YNYoshimi Niwa
Yoshimi Niwa
RMRyutaro Mori
Ryutaro Mori
MOMai Okawa
Mai Okawa
ANAkira Nakakami
Akira Nakakami
Manabu FutamuraManabu Futamura
Manabu Futamura
Background: Breast cancer remains a leading cause of cancer-related deaths despite advances in its diagnosis and treatment. Accurate evaluation of the response to neoadjuvant chemotherapy (NAC), especially in HER2-positive and triple-negative subtypes, is critical. The current methods, including imaging and liquid biopsies, have limitations. N-NOSE, a novel urine-based cancer screening test using Caenorhabditis elegans (C. elegans) chemotaxis, offers a non-invasive alternative. This study investigates the potential of N-NOSE to predict the NAC response in breast cancer patients for improved treatment evaluations. Materials and Methods: This prospective study enrolled 36 breast cancer patients undergoing NAC and surgery to assess the predictive power of the N-NOSE method using urine samples. A chemotaxis analysis of C. elegans was used to calculate the index reduction scores (IRS1–3), reflecting the changes in tumor-related odorants across the treatment stages. Results: Between August 2020 and May 2023, 36 breast cancer patients were enrolled to evaluate the predictive value of N-NOSE IRSs for NAC response. A pathological complete response (pCR) was achieved in 36.1% of the patients. Among the three IRS types analyzed in the 35 patients, IRS3, which showed the IRS at pre-treatment minus that after surgery, showed the highest predictive performance for a pCR, with an AUC of 0.75, indicating its potential utility as a non-invasive biomarker for treatment response evaluations. Conclusions: Index reduction scores evaluated using the N-NOSE method may reflect the efficacy of NAC in breast cancer patients. Future large-scale and multi-institutional prospective studies are warranted.


1 January 2021 in Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons)
Verified
Journal Article
Open access
PDF file
ANAkira Nakakami
Akira Nakakami
Manabu FutamuraManabu Futamura
Manabu Futamura
YHYuichi Hayashi
Yuichi Hayashi
KNKei Noguchi
Kei Noguchi
RMRyutaro Mori
Ryutaro Mori
KYKazuhiro Yoshida
Kazuhiro Yoshida
筋強直性ジストロフィー1型(Myotonic dystrophy type 1,DM1)は,ミオトニア現象を伴う常染色体優性遺伝性筋疾患である.腫瘍の合併率が高い点で重要な疾患であるが,心合併症や呼吸不全の進行により腫瘍に対する外科手術困難の原因にもなる.そのため,DM1と腫瘍の両者を評価し,治療方針を決定することが重要である.われわれは,DM1に巨大葉状腫瘍を合併した症例を経験したので報告する.症例は39歳女性,特発性慢性呼吸不全の診断のもと,近医で経過観察されていた.左乳房腫瘤が約20cmまで増大し,治療目的に当科に紹介となった.遺伝子検査からDM1と診断し,左乳房腫瘤は,葉状腫瘍と診断した.外科手術を検討したが,DM1によるⅡ型呼吸不全の増悪により,手術療法は断念し,看取りの方針とした.DM1は,腫瘍合併リスクが高いことから,腫瘍早期発見のため適切なスクリーニングの施行,治療法の選択や治療時期の検討が必要である.